

EUR Research Information Portal

Prognosis and Treatment of Primary Biliary Cholangitis : a new name – a new era

Publication status and date:

Published: 10/01/2020

Document Version

Other version

Citation for the published version (APA):

Harms, M. (2020). Prognosis and Treatment of Primary Biliary Cholangitis : a new name – a new era. [Doctoral Thesis, Erasmus University Rotterdam]. Erasmus Universiteit Rotterdam (EUR).

[Link to publication on the EUR Research Information Portal](#)

Terms and Conditions of Use

Except as permitted by the applicable copyright law, you may not reproduce or make this material available to any third party without the prior written permission from the copyright holder(s). Copyright law allows the following uses of this material without prior permission:

- you may download, save and print a copy of this material for your personal use only;
- you may share the EUR portal link to this material.

In case the material is published with an open access license (e.g. a Creative Commons (CC) license), other uses may be allowed. Please check the terms and conditions of the specific license.

Take-down policy

If you believe that this material infringes your copyright and/or any other intellectual property rights, you may request its removal by contacting us at the following email address: openaccess.library@eur.nl. Please provide us with all the relevant information, including the reasons why you believe any of your rights have been infringed. In case of a legitimate complaint, we will make the material inaccessible and/or remove it from the website.

PROPOSITIONS

pertaining to the thesis 'Prognosis and Treatment of PBC – a new name, a new era'

1. The strong association between ursodeoxycholic acid treatment and prolonged transplant-free survival justifies the advice for lifelong treatment of all patients suffering from PBC. *(this thesis)*
2. The majority of ursodeoxycholic acid-treated patients with PBC nowadays remains spared of major non-neoplastic cirrhosis-related complications. *(this thesis)*
3. Despite a strong initial decrease in the number of liver transplantations for PBC in Europe during the past decades, we have now reached a plateau phase in which a remaining group of patients with PBC still depends on liver transplantation to prevent premature death. *(this thesis)*
4. Treatment effects of fenofibrate and bezafibrate as add-on treatment to UDCA in patients with PBC are comparable. *(this thesis)*
5. Therapeutic goals should strive beyond normalization of bilirubin in patients with PBC, as a value lower than the currently accepted limit of normal is associated with a reduced risk of liver transplantation and death. *(this thesis)*
6. The data revolution has changed not only the world of science, but every aspect of our lives.
7. Doctors are more likely to change their ways based on evidence of clinical benefit, than they are to de-adopt their practices based on evidence of harm. *(Erin Niven, JAMA, 2015)*
8. Exercising is associated with the improvement of overall happiness. *(Sammi Chekroud, The Lancet Psychiatry, 2018)*
9. The call for transparency impedes efficient spending of our health care budget. *(Sander Heijne, De Correspondent, 2015)*
10. What gets us into trouble is not what we don't know, it's what we know for sure but just ain't so. *(Mark Twain)*
11. C'est le ton qui fait la musique.